170 related articles for article (PubMed ID: 30836448)
21. Smac Mimetics to Therapeutically Target IAP Proteins in Cancer.
Fulda S
Int Rev Cell Mol Biol; 2017; 330():157-169. PubMed ID: 28215531
[TBL] [Abstract][Full Text] [Related]
22. SMAC-expression in denervated human skeletal muscle as a potential inhibitor of coexpressed inhibitor-of-apoptosis proteins.
Tews DS; Behrhof W; Schindler S
Appl Immunohistochem Mol Morphol; 2008 Jan; 16(1):66-70. PubMed ID: 18091317
[TBL] [Abstract][Full Text] [Related]
23. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs).
Rathore R; McCallum JE; Varghese E; Florea AM; Büsselberg D
Apoptosis; 2017 Jul; 22(7):898-919. PubMed ID: 28424988
[TBL] [Abstract][Full Text] [Related]
24. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
25. The SMAC mimetic LCL-161 selectively targets JAK2
Craver BM; Nguyen TK; Nguyen J; Nguyen H; Huynh C; Morse SJ; Fleischman AG
Exp Hematol Oncol; 2020; 9():1. PubMed ID: 31908904
[TBL] [Abstract][Full Text] [Related]
26. Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport.
Talbott RL; Borzilleri RM; Chaudhry C; Fargnoli J; Shen H; Fairchild C; Barnhart B; Ortega M; McDonagh TE; Vuppugalla R; Vite GD; Hunt JT; Gottardis M; Naglich JG
Exp Cell Res; 2015 Nov; 338(2):251-60. PubMed ID: 26302264
[TBL] [Abstract][Full Text] [Related]
27. SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases.
Jensen S; Seidelin JB; LaCasse EC; Nielsen OH
Sci Signal; 2020 Feb; 13(619):. PubMed ID: 32071170
[TBL] [Abstract][Full Text] [Related]
28. Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer.
Lee KM; Lee H; Han D; Moon WK; Kim K; Oh HJ; Choi J; Hwang EH; Kang SE; Im SA; Lee KH; Ryu HS
Breast Cancer Res; 2020 Nov; 22(1):130. PubMed ID: 33239070
[TBL] [Abstract][Full Text] [Related]
29. Smac mimetic promotes TNF-α to induce apoptosis of gallbladder carcinoma cells.
Chen M; Huang M; Chen W; Jiang X; Su W; Wang X; Tang N; She F; Chen Y
Cell Signal; 2020 Aug; 72():109654. PubMed ID: 32334028
[TBL] [Abstract][Full Text] [Related]
30. Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells.
Gerges S; Rohde K; Fulda S
Cancer Lett; 2016 May; 375(1):127-132. PubMed ID: 26944210
[TBL] [Abstract][Full Text] [Related]
31. Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy.
Mohana-Kumaran N; Hill DS; Allen JD; Haass NK
Pigment Cell Melanoma Res; 2014 Jul; 27(4):525-39. PubMed ID: 24655414
[TBL] [Abstract][Full Text] [Related]
32. Smac mimetics as IAP antagonists.
Fulda S
Semin Cell Dev Biol; 2015 Mar; 39():132-8. PubMed ID: 25550219
[TBL] [Abstract][Full Text] [Related]
33. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
Fulda S; Wick W; Weller M; Debatin KM
Nat Med; 2002 Aug; 8(8):808-15. PubMed ID: 12118245
[TBL] [Abstract][Full Text] [Related]
34. Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide.
Bartling B; Lewensohn R; Zhivotovsky B
Exp Cell Res; 2004 Aug; 298(1):83-95. PubMed ID: 15242764
[TBL] [Abstract][Full Text] [Related]
35. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.
Matzinger O; Viertl D; Tsoutsou P; Kadi L; Rigotti S; Zanna C; Wiedemann N; Vozenin MC; Vuagniaux G; Bourhis J
Radiother Oncol; 2015 Sep; 116(3):495-503. PubMed ID: 26096848
[TBL] [Abstract][Full Text] [Related]
36. Smac/DIABLO and colon cancer.
Anguiano-Hernandez YM; Chartier A; Huerta S
Anticancer Agents Med Chem; 2007 Jul; 7(4):467-73. PubMed ID: 17630921
[TBL] [Abstract][Full Text] [Related]
37. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
[TBL] [Abstract][Full Text] [Related]
38. SMAC Mimetics Synergistically Cooperate with HDAC Inhibitors Enhancing TNF-α Autocrine Signaling.
Shibuya Y; Kudo K; Zeligs KP; Anderson D; Hernandez L; Ning F; Cole CB; Fergusson M; Kedei N; Lyons J; Taylor J; Korrapati S; Annunziata CM
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831656
[TBL] [Abstract][Full Text] [Related]
39. IAP proteins: sticking it to Smac.
Duckett CS
Biochem J; 2005 Jan; 385(Pt 1):e1-2. PubMed ID: 15588250
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.
Zobel K; Wang L; Varfolomeev E; Franklin MC; Elliott LO; Wallweber HJ; Okawa DC; Flygare JA; Vucic D; Fairbrother WJ; Deshayes K
ACS Chem Biol; 2006 Sep; 1(8):525-33. PubMed ID: 17168540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
